Penumbra, Inc.
General ticker "PEN" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $12.2B (TTM average)
Penumbra, Inc. follows the US Stock Market performance with the rate: 10.2%.
Estimated limits based on current volatility of 0.4%: low 319.98$, high 322.32$
Factors to consider:
- Total employees count: 4700 (+4.4%) as of 2025
- US accounted for 77.8% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Economic downturns and volatility, Manufacturing issues, Inventory write downs, Geopolitical risks, Regulatory and compliance
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [232.53$, 345.53$]
- 2026-12-31 to 2027-12-31 estimated range: [233.04$, 348.11$]
Financial Metrics affecting the PEN estimates:
- Negative: with PPE of 82.2 at the end of fiscal year the price was high
- Negative: Operating cash flow per share per price, % of 1.94 <= 2.37
- Positive: Inventory ratio change, % of -1.84 <= -1.30
- Positive: 11.29 < Operating profit margin, % of 13.48
- Positive: 69.38 < Shareholder equity ratio, % of 78.16 <= 81.92
- Positive: 7.19 < Return on assets ratio (scaled to [-100,100]) of 8.87
- Positive: Industry inventory ratio change (median), % of 0.70 <= 1.15
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -3.46 <= 0
Short-term PEN quotes
Long-term PEN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,058.52MM | $1,194.62MM | $1,403.66MM |
| Operating Expenses | $984.97MM | $1,185.34MM | $1,214.42MM |
| Operating Income | $73.55MM | $9.28MM | $189.25MM |
| Non-Operating Income | $6.10MM | $11.59MM | $15.88MM |
| R&D Expense | $102.64MM | $94.78MM | $89.77MM |
| Income(Loss) | $79.65MM | $20.87MM | $205.12MM |
| Taxes | $-11.30MM | $6.86MM | $27.44MM |
| Net Income(Loss)* | $90.95MM | $14.01MM | $177.69MM |
| Stockholders Equity | $1,178.94MM | $1,150.93MM | $1,427.60MM |
| Inventory | $388.02MM | $406.74MM | $431.55MM |
| Assets | $1,556.31MM | $1,533.18MM | $1,826.52MM |
| Operating Cash Flow | $97.33MM | $168.48MM | $238.66MM |
| Capital expenditure | $15.21MM | $21.18MM | $63.73MM |
| Investing Cash Flow | $-16.08MM | $77.62MM | $-404.59MM |
| Financing Cash Flow | $16.20MM | $-87.01MM | $26.53MM |
| Earnings Per Share** | $2.37 | $0.36 | $4.57 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.